Home Microbiology SARS-CoV

SARS-CoV

Microbiology

S6 Kinase MEK p38 MAPK Raf ERK MNK TOPK Mixed Lineage Kinase TAK1 KLF MAPKAPK2

Isoform-selective Products

  • All (21)
  • SARS-CoV Inhibitors (20)
  • New SARS-CoV Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8969 Molnupiravir (EIDD-2801) Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.
Antioxidants (Basel), 2025, 14(8)945
Biomed Res, 2025, 46(2):37-50
Antiviral Res, 2024, 225:105840
S9866 Nirmatrelvir (PF-07321332)

Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (Mpro, also referred to as 3CL protease) with an ki of 3.11 nM. It binds directly to the catalytic cysteine (Cys145) residue of the enzyme.
Antioxidants (Basel), 2025, 14(8)945
Commun Biol, 2025, 8(1):1061
Sci Rep, 2025, 15(1):11307
S0833 EIDD-1931 (NHC) EIDD-1931 (NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. This compound has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir.
Microbiol Spectr, 2025, 13(4):e0269224
Nucleic Acids Res, 2023, 10.1093/nar/gkad1002
NPJ Digit Med, 2022, 5(1):83
E1900 Simnotrelvir Simnotrelvir(SIM0417, SARS-CoV-2-IN-41) is an inhibitor of coronavirus main proteinase (3CLpro) (SARS-CoV-2 3CLpro) with an IC50 of 24 nM. It has a potential anti-SARS-CoV-2 activity.
E7079 Ensitrelvir Ensitrelvir (S-217622) is an oral, non-covalent, non-peptidic inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 13 nM. It also exhibits antiviral activity in vitro and is a potential oral agent for treating COVID-19.
S0793 ML188 ML188 is a non-covalent SARS-CoV 3CLpro inhibitor with IC50 of 1.5 μM. This compound has antiviral activity.
S0875 XP-59 XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM.
E1112 GS-621763 GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM. 
E0613 TC-067533 TC-067533 is a potent SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 of 8.7 μM.
E1111 VV116 VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
E1131 Ensitrelvir fumarate S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM.
Emerg Microbes Infect, 2025, 14(1):2552716
S9963 paquinimod Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
Redox Biol, 2025, 81:103532
J Inflamm Res, 2025, 18:14941-14959
Cell Rep, 2024, 43(11):114900
E3159 Caryophylli Flos Extract Caryophylli Flos Extract is drawed from Caryophylli Flos, which exerts inhibitory effects on the wild-type SARS-CoV and HIV/SARS-CoV S pseudovirus infections, showing moderate IC50 inhibitory effects (<100 μg/mL) at 30.3 ± 2.6 μg/mL and 58.8 ± 5.6 μg/mL, respectively. 
E1174 Coronastat(NK01-63) Coronastat(NK01-63) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.
E1013 Bemnifosbuvir Hemisulfate (AT-527)

Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511, which is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.
S1386 Nafamostat mesilate (FUT-175) Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor used as an anticoagulant during hemodialysis. It blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. This compound also attenuates inflammation and apoptosis.
J Immunother Cancer, 2024, 12(11)e009805
Cell Death Dis, 2024, 15(2):109
CNS Neurosci Ther, 2024, 30(6):e14822
Verified customer review of Nafamostat mesilate (FUT-175)
S9731 PF-00835231 PF-00835231 is a 3CLpro (Mpro) inhibitor that may targets SARS-CoV-2 protease 3CLpro as a potential new treatment for COVID-19.
Mol Cell, 2022, S1097-2765(22)00433-6
Bioorg Med Chem Lett, 2022, 66:128732
Nat Commun, 2021, 12(1):6786
S0515 PLpro inhibitor  PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.
PLoS Pathog, 2023, 19(8):e1011592
PLoS Pathog, 2023, 19(8):e1011592
bioRxiv, 2022, 2022.08.06.503039
S6845 GRL0617 GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. This compound inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.
J Virol, 2024, e0085524.
S3553 Riamilovir Riamilovir (Triazavirin) is a broad-spectrum antiviral drug candidate, which can be used for potential application against the Coronavirus 2019-nCoV.
E0052 Merafloxacin Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses.
S8969 Molnupiravir (EIDD-2801) Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.
Antioxidants (Basel), 2025, 14(8)945
Biomed Res, 2025, 46(2):37-50
Antiviral Res, 2024, 225:105840
S9866 Nirmatrelvir (PF-07321332)

Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (Mpro, also referred to as 3CL protease) with an ki of 3.11 nM. It binds directly to the catalytic cysteine (Cys145) residue of the enzyme.
Antioxidants (Basel), 2025, 14(8)945
Commun Biol, 2025, 8(1):1061
Sci Rep, 2025, 15(1):11307
S0833 EIDD-1931 (NHC) EIDD-1931 (NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. This compound has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir.
Microbiol Spectr, 2025, 13(4):e0269224
Nucleic Acids Res, 2023, 10.1093/nar/gkad1002
NPJ Digit Med, 2022, 5(1):83
E1900 Simnotrelvir Simnotrelvir(SIM0417, SARS-CoV-2-IN-41) is an inhibitor of coronavirus main proteinase (3CLpro) (SARS-CoV-2 3CLpro) with an IC50 of 24 nM. It has a potential anti-SARS-CoV-2 activity.
E7079 Ensitrelvir Ensitrelvir (S-217622) is an oral, non-covalent, non-peptidic inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 13 nM. It also exhibits antiviral activity in vitro and is a potential oral agent for treating COVID-19.
S0793 ML188 ML188 is a non-covalent SARS-CoV 3CLpro inhibitor with IC50 of 1.5 μM. This compound has antiviral activity.
S0875 XP-59 XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM.
E1112 GS-621763 GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM. 
E0613 TC-067533 TC-067533 is a potent SARS-CoV papain-like protease (PLpro) inhibitor with an IC50 of 8.7 μM.
E1111 VV116 VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM.
E1131 Ensitrelvir fumarate S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM.
Emerg Microbes Infect, 2025, 14(1):2552716
S9963 paquinimod Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
Redox Biol, 2025, 81:103532
J Inflamm Res, 2025, 18:14941-14959
Cell Rep, 2024, 43(11):114900
E3159 Caryophylli Flos Extract Caryophylli Flos Extract is drawed from Caryophylli Flos, which exerts inhibitory effects on the wild-type SARS-CoV and HIV/SARS-CoV S pseudovirus infections, showing moderate IC50 inhibitory effects (<100 μg/mL) at 30.3 ± 2.6 μg/mL and 58.8 ± 5.6 μg/mL, respectively. 
E1174 Coronastat(NK01-63) Coronastat(NK01-63) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle.
E1013 Bemnifosbuvir Hemisulfate (AT-527)

Bemnifosbuvir Hemisulfate (AT-527, RG-6422, RO 7496998) is a hemi-sulfate salt of AT-511, which is a potent inhibitor of SARS-CoV-2 with an EC90 of 0.47 μM.
S1386 Nafamostat mesilate (FUT-175) Nafamostat mesilate (FUT-175) is a synthetic serine protease inhibitor used as an anticoagulant during hemodialysis. It blocks activation of SARS-CoV-2 and is investigated as a new treatment option for COVID-19. This compound also attenuates inflammation and apoptosis.
J Immunother Cancer, 2024, 12(11)e009805
Cell Death Dis, 2024, 15(2):109
CNS Neurosci Ther, 2024, 30(6):e14822
 Verified customer review of Nafamostat mesilate (FUT-175)
S9731 PF-00835231 PF-00835231 is a 3CLpro (Mpro) inhibitor that may targets SARS-CoV-2 protease 3CLpro as a potential new treatment for COVID-19.
Mol Cell, 2022, S1097-2765(22)00433-6
Bioorg Med Chem Lett, 2022, 66:128732
Nat Commun, 2021, 12(1):6786
S0515 PLpro inhibitor  PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.
PLoS Pathog, 2023, 19(8):e1011592
PLoS Pathog, 2023, 19(8):e1011592
bioRxiv, 2022, 2022.08.06.503039
S6845 GRL0617 GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. This compound inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.
J Virol, 2024, e0085524.
E0052 Merafloxacin Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses.